GABRR1 — GABA-A Receptor Rho1 Subunit

📖 Wiki Page

gene1373 wordssynced 2026-04-02

GABRR1 — GABA-A Receptor Rho1 Subunit

Overview

...

GABRR1 — GABA-A Receptor Rho1 Subunit

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRR1 — GABA-A Receptor Rho1 Subunit</th>
</tr>
<tr>
<td class="label">Agonist</td>
<td>GABA, CACA</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>TPMPA, PTT</td>
</tr>
<tr>
<td class="label">Bicuculline sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Benzodiazepine sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">rs1913510</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1893532</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1057396</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs832753</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GABRR2 (rho2)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABRR3 (rho3)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABAC1</td>
<td>Co-assembly</td>
</tr>
<tr>
<td class="label">VILIP-1</td>
<td>Physical binding</td>
</tr>
<tr>
<td class="label">GRIP1</td>
<td>Scaffold interaction</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>PSD binding</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Expression Change</td>
</tr>
<tr>
<td class="label">AD hippocampus</td>
<td>Downregulated</td>
</tr>
<tr>
<td class="label">PD substantia nigra</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Epilepsy tissue</td>
<td>Altered splicing</td>
</tr>
<tr>
<td class="label">Aging brain</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">TPMPA</td>
<td>Variable response</td>
</tr>
<tr>
<td class="label">Baclofen</td>
<td>Altered sensitivity</td>
</tr>
<tr>
<td class="label">GABA derivatives</td>
<td>Differential response</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Application</td>
</tr>
<tr>
<td class="label">qPCR</td>
<td>mRNA expression</td>
</tr>
<tr>
<td class="label">Western blot</td>
<td>Protein levels</td>
</tr>
<tr>
<td class="label">IHC</td>
<td>Localization</td>
</tr>
<tr>
<td class="label">Radioligand binding</td>
<td>Receptor density</td>
</tr>
<tr>
<td class="label">Electrophysiology</td>
<td>Function</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GABRR1 (GABA-A Receptor Rho1 Subunit) encodes the ρ1 (rho1) subunit of GABA receptors, originally termed the GABA-C receptor[@enz2017]. The rho1 subunit forms homomeric or heteromeric GABA-gated chloride channels that are structurally similar to GABA-A receptors but pharmacologically distinct. This gene is located at chromosome 9q33.1 and is expressed in various brain regions including the retina, spinal cord, suprachiasmatic nucleus, and substantia nigra.

Molecular Biology

Protein Structure

The GABRR1 protein (UniProt: P28476) contains:

Extracellular N-terminus: Contains the GABA binding site
Transmembrane domains: Four helical transmembrane segments (TM1-4)
Intracellular loop: Between TM3 and TM4, involved in phosphorylation
C-terminal region: Mediates subunit assembly and trafficking

Rho1-containing receptors form pentameric assemblies, typically as homomers of rho1 or heteromers with rho2 (GABRR2)[@primrose2018]. These receptors are insensitive to bicuculline and benzodiazepines but are strongly activated by GABA and blocked by antagonists like TPMPA.

Expression Pattern

GABRR1 shows distinctive expression in the nervous system:

Retina: Rod bipolar cells, cone bipolar cells, horizontal cells[@kourennyi2016]
Spinal cord: Dorsal horn neurons
Suprachiasmatic nucleus: Circadian rhythm regulation[@ehlen2017]
Superior colliculus
Olfactory bulb
Substantia nigra pars reticulata: Modulation of motor circuits
Hippocampus: Synaptic plasticity and memory

Role in Neurodegenerative Diseases

Alzheimer's Disease

GABRR1 expression is altered in Alzheimer's disease (AD) pathophysiology. Research has shown that:

GABAergic dysfunction: Progressive loss of GABAergic signaling contributes to network hyperactivity in AD[@iwai2019]

Amyloid interaction: Aβ oligomers can modulate GABA(C) receptor function, affecting inhibitory tone

Memory consolidation: GABA(C) receptors play a role in hippocampal memory processes that are disrupted in AD[@kutsumura2019]

Neuroprotection: GABA(C) receptor agonists have shown neuroprotective effects against Aβ toxicity in cellular models[@chen2019]

Parkinson's Disease

In Parkinson's disease (PD), GABRR1 is implicated through:

Substantia nigra alterations: GABA(C) receptor expression changes in the substantia nigra pars reticulata affecting motor output[@tomiyama2020]

Dopaminergic interactions: GABAergic signaling modulates dopaminergic neuron survival[@kim2017]

Motor circuits: GABA(C) receptors in basal ganglia circuits influence motor control

Therapeutic targets: Modulating GABA(C) receptors may provide novel PD therapeutic strategies

Other Neurodegenerative Conditions

Epilepsy: GABRR1 variants are associated with juvenile myoclonic epilepsy and generalized epilepsy syndromes[@maljevic2018]
Age-related cognitive decline: Genetic polymorphisms in GABRR1 correlate with cognitive decline in aging populations[@nakamura2018]
Neuroinflammation: GABA(C) receptors on microglia modulate inflammatory responses[@sato2019]

Signaling Mechanisms

Receptor Pharmacology

GABRR1-containing receptors exhibit unique pharmacological properties:

Signal Transduction

GABA(C) receptor activation leads to:

Cl- influx (hyperpolarization)

Reduced neuronal excitability

Modulation of voltage-gated calcium channels

Downstream effects on MAPK/ERK and PI3K/Akt pathways

Therapeutic Implications

Drug Development

GABRR1 represents a potential therapeutic target for:

Neuroprotective agents: GABA(C) agonists as neuroprotective compounds[@matsumoto2019]

Memory enhancement: Targeting GABA(C) receptors in memory circuits

Motor symptoms: Modulating basal ganglia GABAergic signaling for PD

Seizure control: GABRR1 modulators for epilepsy treatment

Gene Therapy Approaches

Recent research has explored:

Viral vector delivery of GABRR1 for restoring GABAergic function
CRISPR-based approaches for correcting pathogenic variants
RNA-based therapeutics targeting GABRR1 expression

Common Variants and Genetic Studies

Genome-wide association studies have identified GABRR1 variants associated with:

Epilepsy susceptibility
Sleep disorders
Cognitive function in aging
Response to GABAergic drugs

Research Directions

Current Areas of Investigation

Structural studies: Cryo-EM structures of GABA(C) receptors

Therapeutic screening: High-throughput screening for GABA(C) modulators

Animal models: GABRR1 knockout and knock-in models

Clinical translation: Biomarker development for GABA(C)-targeted therapies

Future Perspectives

Development of subtype-selective GABA(C) receptor modulators
Personalized medicine approaches based on GABRR1 genotype
Combination therapies targeting multiple GABA receptor subtypes

Animal Models and Experimental Systems

Mouse Models

GABRR1 knockout mice (Gabrr1-/-) have been generated and characterized:

Behavioral phenotypes:

Increased locomotor activity in open field tests
Altered circadian rhythm patterns
Enhanced seizure susceptibility
Memory consolidation deficits in Morris water maze

Neurobiological findings:

Reduced GABA-evoked currents in retinal bipolar cells
Altered inhibitory synaptic transmission in the hippocampus
Changes in neuronal excitability in the substantia nigra pars reticulata
Dysregulated dopamine release in basal ganglia circuits

Zebrafish Models

Zebrafish gabrr1 morphants show:

Developmental abnormalities in retinal patterning
Altered GABAergic neuron migration
Motor circuit formation defects

Cell Culture Systems

Expression systems:

HEK293T cells for receptor characterization
Xenopus oocytes for electrophysiological studies
SH-SY5Y neuroblastoma cell lines for disease modeling

Primary cultures:

Primary cortical neurons from wild-type and knockout mice
Retinal bipolar cell cultures
Midbrain dopaminergic neuron cultures

Protein Interactions and Network

Direct Protein Interactions

GABRR1 interacts with several proteins:

Signaling Network Integration

GABRR1 participates in several signaling networks:

GABAergic signaling: Primary receptor for inhibitory transmission
Dopaminergic modulation: Cross-talk with D1/D2 receptor pathways
Circadian clock integration: SCN signaling
Motor control circuits: Basal ganglia output modulation

Differential Expression in Disease

GABRR1 expression is altered in several disease states:

Clinical Studies and Trials

Biomarker Studies

GABRR1 has been investigated as a potential biomarker:

Cerebrospinal fluid studies:

GABRR1 protein levels measurable in CSF
Correlations with disease severity
Potential for disease progression monitoring

Genetic studies:

Variant associations with disease risk
Pharmacogenomic responses to GABAergic drugs

Clinical Trials Targeting GABA(C) Receptors

Several clinical approaches have been investigated:

Agonist trials: GABA(C) receptor agonists for neuroprotection

Antagonist studies: TPMPA derivatives for cognitive enhancement

Allosteric modulators: Positive allosteric modulators in development

Gene therapy approaches: AAV-GABRR1 delivery trials

Observational Studies

Longitudinal studies of GABRR1 variants and cognitive decline
Imaging studies correlating receptor density with brain function
Post-mortem brain studies in AD and PD

Pharmacogenomics

Drug Responses

GABRR1 variants affect responses to:

Personalized Medicine Potential

Genotype-guided therapy selection
Dose optimization based on receptor function
Combination therapy considerations

Research Methods

Detection Methods

Manipulation Methods

CRISPR-Cas9 knockout
siRNA knockdown
Overexpression constructs
Cre-lox conditional knockout

Conclusion and Future Perspectives

GABRR1 represents a unique GABA receptor subtype with distinctive pharmacological properties and brain distribution. While traditionally considered a retinal receptor, increasing evidence supports important roles in various brain regions and neurodegenerative diseases. The development of selective GABA(C) receptor modulators offers therapeutic opportunities for AD, PD, and other neurological conditions. However, challenges remain in achieving brain-penetrant, subtype-selective compounds and understanding the full spectrum of GABRR1 functions in the human brain. Future research should focus on:

Development of brain-penetrant GABA(C) receptor modulators

Understanding heteromeric receptor composition in vivo

Translating preclinical findings to clinical applications

Identifying biomarker applications for patient stratification

Cross-References

[GABRR2](/genes/gabrr2) — GABA-A receptor rho2 subunit
[GABRR3](/genes/gabrr3) — GABA-A receptor rho3 subunit
[GABA Signaling in Neurodegeneration](/mechanisms/gaba-signaling)
[Suprachiasmatic Nucleus and Circadian Rhythms](/brain-regions/suprachiasmatic-nucleus)
[Substantia Nigra Pars Reticulata](/brain-regions/substantia-nigra)
[Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
[Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)

External Links

[NCBI Gene: GABRR1](https://www.ncbi.nlm.nih.gov/gene/2567)
[UniProt: GABRR1](https://www.uniprot.org/uniprot/P28476)
[IUPHAR: GABAρ1 receptor](https://www.guidetopharmacology.org/graphql/receptor/GPCR:2052)
[Ensembl: GABRR1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146228)
[OMIM: GABRR1](https://www.omim.org/entry/137161)

📖 View canonical wiki page →